Please login to the form below

Not currently logged in
Email:
Password:

CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

Gilead and Arcus complete closing of ten-year immunotherapy partnership

Gilead and Arcus complete closing of ten-year immunotherapy partnership

It also signed a $2.35bn deal with Nurix for protein degradation drugs for cancer and other diseases, as well as a $11.9bn acquisition of CAR-T cell therapy player

Latest news

  • We've got this! We've got this!

    been. All of those changes, from sulphonamides to CAR-T and from regulation to health economics, hit the industry, made us feel uncomfortable and made evolution non-negotiable. ... But our industry rose to that challenge. We didn’t just survive, we

  • FDA approves Roche’s Actemra COVID-19 trial FDA approves Roche’s Actemra COVID-19 trial

    It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with ... T cell therapies for cancer.

  • China backs use of Roche’s Actemra for coronavirus China backs use of Roche’s Actemra for coronavirus

    and CRS associated with CAR-T cell therapies for cancer.

  • Gilead swoops on Forty Seven with $4.9bn all-cash deal Gilead swoops on Forty Seven with $4.9bn all-cash deal

    immune system by sending out a ‘don’t eat me’ signal to macrophage cells. ... a run of M&A that hit a peak in 2017 with Gilead’s $11.9bn acquisition of CAR-T cell therapy player Kite Pharma.

  • GSK pays $50m upfront to tap Immatics’ cell therapy platform GSK pays $50m upfront to tap Immatics’ cell therapy platform

    It’s a similar approach to CAR-T therapy, but according to Immatics TCRs should have broader utility because they can be targeted at proteins inside cancer cells. ... Moreover, unlike currently-approved CAR-T therapies for cancer like Novartis’

More from news
Approximately 48 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged hospital visits (eg, CAR-T and gene therapies).

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    The interleukin-6 receptor antagonist is approved for use in indications including the management of cytokine release syndrome in CAR-T patients.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... It now has more than 300 CAR-T clinical trials underway and collaboration with European and

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of

More from intelligence
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • Perspective: the patient edition

    The ALS patient journey. An article on CAR-T service design. Thought provoking content on clinical trial access and the social determinants of healthcare, and on precision and personalised medicine.

  • The balancing act that’s keeping pharma and biotech market access on its toes

    CAR-T cell therapy costs  close to $500, 000 per patient in the US, and  300, 000 in Europe.

  • Launch Excellence 2020

    How can you use insights to understand customers decision-making behaviour? What are you missing in your CAR-T service launch?

  • Understanding the evolving CAR-T market

    The CAR-T was their last chance and only hope. Astoundingly, 83% achieved overall remission within just three months of treatment. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

More from PMHub
Approximately 4 fully matching, plus 10 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics